Division of Pulmonary and Critical Care Medicine, Department of Medicine, Cooper University Hospital, Robert Wood Johnson Medical School, Camden, NJ 08103, USA.
Crit Care Clin. 2011 Jul;27(3):561-87. doi: 10.1016/j.ccc.2011.05.001.
The mortality for acute respiratory distress syndrome remains unacceptably high. Two vasodilators, inhaled prostacyclin and inhaled nitric oxide, are reviewed in this article. Knowledge of inhaled prostacyclin has grown substantially in the past 30 years, but less research exists about its utility in acute respiratory distress syndrome. Inhaled prostacyclin and other prostaglandin derivatives are used in acute respiratory distress syndrome with increasing frequency. Currently, only randomized controlled trials exist for inhaled nitric oxide in acute respiratory distress syndrome patients. Randomized controlled trials with consistent dosing methods are needed for both vasodilators to better define their role in the treatment of acute respiratory distress syndrome.
急性呼吸窘迫综合征的死亡率仍然高得令人无法接受。本文回顾了两种血管扩张剂，吸入前列环素和吸入一氧化氮。在过去的 30 年中，人们对吸入前列环素的认识有了实质性的增长，但关于其在急性呼吸窘迫综合征中的应用的研究较少。吸入前列环素和其他前列腺素衍生物在急性呼吸窘迫综合征中的使用频率越来越高。目前，只有吸入一氧化氮治疗急性呼吸窘迫综合征的随机对照试验。需要对这两种血管扩张剂进行具有一致剂量方法的随机对照试验，以更好地确定它们在急性呼吸窘迫综合征治疗中的作用。
